Atlas Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Atlas Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$281	–	1034
2025 Q4	$281	Buy	+8	New	+$283	﹤0.01%	942

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Atlas Capital Advisors's VKTX Position: Q1 2026 in Review

Atlas Capital Advisors sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 8 shares — an estimated $281 sold.

Atlas Capital Advisors first reported a position in VKTX in Q4 2025 and held it in 1 quarter. The position peaked at $281 in Q4 2025. 414 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Atlas Capital Advisors reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Atlas Capital Advisors sold 8 Viking Therapeutics shares in Q1 2026, an estimated $281.
Atlas Capital Advisors first reported a position in Viking Therapeutics in Q4 2025 and held it in 1 quarter.
Atlas Capital Advisors's Viking Therapeutics position peaked at $281 in Q4 2025.
414 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.